

[Date]

Insert Network Provider NAME
ADDRESS

Subject: HEDIS/Medicare 5 Star Measures

Dear <<Provider Contact Name>>:

We are committed to working with you to improve the quality of care and health outcomes for your HAP patients. The Healthcare Effectiveness Data and Information Set (HEDIS) and Medicare 5 Star are tools we use to measure many aspects of performance.

We want to partner with you to improve performance for the following two statin drug therapy related quality measures.

Quality Measure	Enclosed Summary Shows	Recommendation for Improvement
Statin therapy for patients with cardiovascular disease (SPC)	Patients (males 21–75 years of age and females 40–75 years of age) with a history of ASCVD and not currently prescribed moderate to high intensity statin therapy.	Addition of moderate to high intensity statin therapy (see table 1 on reverse side)
Statin therapy for patients with diabetes (SUPD)	Patients 40-75 years of age with diabetes and not currently taking any statin therapy.	Addition of statin therapy (<i>any dose</i>)

Please review the summary (on the reverse side) of your patient(s) with gaps in SPC or SUPD as of <<Pharmacy Database analyst to enter date used for latest statin hx>>. This gap can be closed by having your patient start statin therapy.

HAP will pay \$300 for each patient on the summary (on the reverse side) that has a qualifying statin prescription adjudicated at a pharmacy through their prescription benefit card. Payments will be processed in February 2021.

Please ensure each patient is addressed by December 15, 2020.

If you have any questions, please call our Medication Therapy Management (MTM) team at **(866) 766-4707**.

Sincerely,



Vanita Pindolia, PharmD, MBA
Vice President, Ambulatory Clinical Pharmacy Program

TABLE 1. ACC/AHA Statin Intensity Groups

High-intensity Statin Therapy (SPC & SUPD)	Moderate-Intensity Statin Therapy (SPC & SUPD)	Low-Intensity Statin Therapy (SUPD Only)
<ul style="list-style-type: none"> • Atorvastatin 40-80 mg • Rosuvastatin 20-40 mg 	<ul style="list-style-type: none"> • Atorvastatin 10-20 mg • Rosuvastatin 5-10 mg • Simvastatin 20-40 mg • Pravastatin 40-80 mg • Lovastatin 40 mg • Fluvastatin XL 80 mg • Fluvastatin 40 mg BID • Pitavastatin 2-4 mg 	<ul style="list-style-type: none"> • Simvastatin 10 mg • Pravastatin 10-20 mg • Lovastatin 20 mg • Fluvastatin 20-40 mg • Pitavastatin 1 mg

Table adapted from 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45.

TABLE 2. Patient(s) and their applicable quality measures per CMS determination of gap(s) in care:

HAP ID	LAST NAME	FIRST NAME	DOB	SPC measure (High/Mod Intensity)	SUPD measure (Any Intensity)